Cyproterone acetate
Cyproterone acetate is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against androgen receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | 1 | — | 4 | 5 | 11 |
Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 1 | 1 | 2 | 4 |
Hyperandrogenism | D017588 | — | — | — | 2 | 1 | 3 | ||
Menstruation disturbances | D008599 | HP_0400007 | N91.5 | — | — | — | 2 | — | 2 |
Gender dysphoria | D000068116 | F64 | — | — | — | 1 | — | 1 | |
Amenorrhea | D000568 | N91.2 | — | — | — | 1 | — | 1 | |
Dysmenorrhea | D004412 | HP_0100607 | N94.6 | — | — | — | 1 | — | 1 |
Transsexualism | D014189 | F64.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | C61 | — | 1 | 4 | — | 3 | 8 | |
Endometriosis | D004715 | EFO_0001065 | N80 | — | — | 1 | — | — | 1 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | — | — | 1 | |
Adenocarcinoma | D000230 | — | — | 1 | — | — | 1 | ||
Pedophilia | D010378 | F65.4 | — | — | 1 | — | — | 1 | |
Hot flashes | D019584 | — | — | 1 | — | — | 1 | ||
Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | 1 | — | — | 1 | |
Endometrial hyperplasia | D004714 | N85.0 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug interactions | D004347 | — | — | — | — | 1 | 1 | ||
Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | — | 1 | 1 |
Professional burnout | D002055 | — | — | — | — | 1 | 1 | ||
Seborrheic dermatitis | D012628 | L21 | — | — | — | — | 1 | 1 | |
Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | — | — | 1 | 1 |
Gingivitis | D005891 | K05.10 | — | — | — | — | 1 | 1 | |
Periodontal diseases | D010510 | K05.6 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CYPROTERONE ACETATE |
INN | cyproterone |
Description | Cyproterone acetate is a steroid ester resulting from the formal condensation of the carboxy group of acetic acid with the 17-hydroxy group of cyproterone. It is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. It has a role as an androgen antagonist, a progestin and a geroprotector. It is a 20-oxo steroid, a 3-oxo-Delta(4) steroid, a chlorinated steroid, a steroid ester and an acetate ester. It is functionally related to a cyproterone. |
Classification | Small molecule |
Drug class | antiandrogens |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C |
Identifiers
PDB | — |
CAS-ID | 427-51-0 |
RxCUI | — |
ChEMBL ID | CHEMBL139835 |
ChEBI ID | 50743 |
PubChem CID | 9880 |
DrugBank | DB04839 |
UNII ID | E61Q31EK2F (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,179 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
891 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more